Valor pronostico de la biopsia liquida en exosomas circulantes en plasma en el paciente oncológico con diagnostico reciente de metástasis cerebrales
- Carretero Gonzalez, Alberto
- Guillermo de Velasco Oria de Rueda Zuzendaria
- Héctor Peinado Zuzendaria
- Marta Hergueta Redondo Zuzendaria
Defentsa unibertsitatea: Universidad Complutense de Madrid
Fecha de defensa: 2021(e)ko uztaila-(a)k 20
- Luis Paz-Ares Rodríguez Presidentea
- Jose Fermin Perez Regadera Gomez Idazkaria
- Pilar Sánchez Gómez Kidea
- Juan Manuel Sepúlveda Sánchez Kidea
- Francisco González Llanos Fernández de Mesa Kidea
Mota: Tesia
Laburpena
Around 40% of the cancer patients with metastatic tumors will present brain metastases during the course of their disease. Once diagnosed, brain metastases are associated with a decreased overall survival; less than 10% of the patients survive more than 2 years, with a significant impairment in their quality of life.Brain metastases are often associated with immune system impairment. Among other molecules, both STAT3 activity and PD-L1 levels in tumor and immune cells are modulated. The identification of new biomarkers useful in liquid biopsy offers several advantages in brain metastases diagnosis and prognosis, such as their easy accessibility and the possibility of non-invasive dynamic monitoring. Extracellular vesicles have been recently proposed as novel biomarkers especially useful in liquid biopsy due to their secretion in biofluids and their role in cell communication during tumor progression...